Skip to main content

Table 3 Changes in the median (range) blood Tyr concentrations (μmol/L) within and between the CGMP-AA2 and Phe-free L-AA group at baseline, 26 and 52 weeks

From: Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU

Group

Number of subjects

Baseline μmol/L (range)

Wk 26 μmol/L (range)

Wk 52 μmol/L (range)

P value

CGMP-AA2

29

50§* (30–180)

50§ (30–210)

50* (30–170)

§p = 0.916 *p = 0.239

Phe-free L-AA

19

40§§** (40–100)

40§§ (30–105)

40** (30–80)

§§p = 0.672 **p = 0.111

  1. Wilcoxon test § GMP baseline to 26 wk., * GMP baseline to 52 wk
  2. Wilcoxon test §§ L-AA baseline to 26 wk., ** L-AA baseline to 52 wk
  3. ABREVIATIONS: CGMP-AA low phenylalanine glycomacropeptide protein substitute supplemented with L-amino acids, Phe-free L-AA Phenylalanine free L-amino acid supplement
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172